Across TCGA pan-cancer cohorts, RNU6-629P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNU6-629P data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-629P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-629P expression acts as an unfavorable survival marker.
STAD, MESO, and LIHC are the cancer types where RNU6-629P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.